- Advanced search
- Immuno Portal
- Malaria Portal
Compound class: Antibody
Comment: Gimsilumab (MORAb-022) is an investigational, fully human IgG1 monoclonal antibody being evaluated for its potential in the treatment of multiple inflammatory diseases and cancer. It targets granulocyte-macrophage colony stimulating factor (GM-CSF, CSF2), a growth factor involved in autoimmune diseases, such as rheumatoid arthritis, multiple sclerosis and asthma. In the cancer setting, MORAb-022-mediated blocking of CSF2 produces a pro-immunity microenvironment that leads to tumour tissue death in preclinical studies. Peptide sequences (from the WHO INN submission for gimsilumab) match sequences 8 and 12 from Morphotek Inc. patent WO2007092939 , and these sequences belong to monoclonal antibody clone G9 specified in the patent.
1. Sass PM, Nicolaides NE, Grasso L, Li J, Chao Q, Routhier E, Ebel W. (2007)
Antigenic gm-csf peptides and antibodies to gm-csf.
Patent number: WO2007092939. Assignee: Morphotek, Inc.. Priority date: 08/02/2006. Publication date: 16/08/2007.